bluebird bio, Inc. NASDAQ: BLUE
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer
Name | bluebird bio, Inc. |
Ticker | BLUE |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Biopharmaceuticals |
Price
52W Low/High |
31.10
25.62 / 73.84 |
Momentum | Sharp Down |
Market cap | 2.1 B |
1Y Total Return |
-57.00%
Weak |
1Y Volatility |
81.02%
More Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer
Details
Ticker | BLUE |
Name | bluebird bio, Inc. |
ISIN | US09609G1004 |
CUSIP | 09609G100 |
Exchange | NASDAQ |
Sector | Health Care |
Industry | Biopharmaceuticals |
Country | USA |
Currency | U.S. Dollar |
In Index(ices) | NASDAQ Biotechnology Index |
Share as of 2/26/21
Close Price | 31.10 |
52W Low/High | 25.62 / 73.84 |
Market cap | 2.1 B |
1Y Total Return |
-57.00%
Weak |
1Y Volatility |
81.02%
More Risk |
Beta | 1.86 |
PE (trailing) | - |
12M Dividends | - |
Last Dividend Date | - |
Dividend Yield | - |
Fin. Strength
Net Profit Margin | -256.8% |
Cash from Op. / Cur. Liabilities | -2.41 |
Diluted Earnings / Share | -10.98 |
ROE | - |
ROIC | -46.8% |
Price / Revenue | 8.2 |
Price / Book | 1.4 |
Price / CF | -4.3 |
Current Ratio | 6.6 |
Cur.Liabilities / Tot.Liabilities | 0.5 |
Financial Leverage | 0.13 |
in Mils USD |
rolling-year up to September
|
||||||
---|---|---|---|---|---|---|---|
Income Statement | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Revenue |
250
|
54
|
40
|
33
|
6
|
19
|
|
Gross Profit |
245
|
51
|
39
|
31
|
6
|
19
|
|
R&D |
613
|
540
|
421
|
238
|
183
|
119
|
|
EBITDA |
-639
|
-733
|
-516
|
-279
|
-231
|
-132
|
|
Operating Income |
-654
|
-738
|
-532
|
-287
|
-241
|
-137
|
|
Net Income exc. Extra |
-
|
-
|
-
|
-
|
-
|
-
|
|
per Share | |||||||
Diluted avg Shares |
66
|
55
|
53
|
46
|
37
|
36
|
|
EPS exc. Extra |
-10.98
|
-13.00
|
-10.52
|
-7.02
|
-6.47
|
-4.20
|
|
Dividend |
-
|
-
|
-
|
-
|
-
|
-
|
|
Div. Yield (an.) |
-
|
-
|
-
|
-
|
-
|
-
|
|
Balance Sheet | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Total Assets |
1,945
|
1,892
|
2,352
|
1,406
|
918
|
1,018
|
|
Cash, Eq & Invt ShortTerm |
1,230
|
1,180
|
1,695
|
729
|
601
|
707
|
|
Total Current Assets |
1,293
|
1,220
|
1,725
|
759
|
609
|
713
|
|
Total Non-Current Assets |
652
|
672
|
626
|
647
|
309
|
304
|
|
Intangibles |
24
|
29
|
27
|
31
|
35
|
39
|
|
Total Liabilities |
422
|
421
|
351
|
264
|
224
|
129
|
|
Total Current Liabilities |
197
|
196
|
132
|
77
|
68
|
34
|
|
Long Term Debt |
226
|
224
|
219
|
188
|
156
|
95
|
|
Shareholder equity |
1,523
|
1,472
|
2,001
|
1,141
|
695
|
889
|
|
Cash Flow | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Cash from Operations |
-474
|
-535
|
-379
|
-254
|
-154
|
-81
|
|
Depreciation |
19
|
17
|
16
|
12
|
9
|
7
|
|
Cash from Investing |
-50
|
-97
|
-231
|
-477
|
-22
|
-323
|
|
Capex |
33
|
72
|
62
|
56
|
18
|
6
|
|
Cash from Financing |
547
|
21
|
1,324
|
728
|
3
|
732
|
|
Stock Issued |
547
|
21
|
1,322
|
689
|
5
|
732
|
|
Debt (LT) Issued |
0
|
0
|
-1
|
0
|
0
|
0
|
|
Free Cash Flow |
-753
|
-886
|
-782
|
-467
|
-278
|
-306
|
|
Ratios | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
Net Profit Margin |
-
|
-
|
-
|
-
|
-
|
-
|
|
NCFO / Op.Income |
-
|
-
|
-
|
-
|
-
|
-
|
|
Current Ratio |
6.6
|
6.2
|
13.1
|
9.9
|
9.0
|
21.2
|
|
Financial Leverage D/E |
0.13
|
0.13
|
0.08
|
0.14
|
0.14
|
0.05
|
|
Return on Capital Avg |
-46.8%
|
-56.2%
|
-45.1%
|
-34.4%
|
-40.8%
|
-36.2%
|
|
Return on Shareholder Equity |
-
|
-
|
-
|
-
|
-
|
-
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available